Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD ‐ L1 expression: Updated analysis
Cancer Medicine · 2024
DOI: 10.1002/cam4.70036 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yasuyuki Ikezawa und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death‐ligand 1 (PD‐L1) expression is an important issue in clinical practice. We previously conducted a retrospective multicenter observational study of patients with NSCLC and high PD‐L1 expression who received MONO or COMB as a first‐line treatment. Here, we report updated data and evaluate the long‐term outcomes.
Methods
We performed a retrospective multicenter study of 298 patients with NSCLC and high PD‐L1 expression who received MONO or COMB as first‐line treatment between December 2018 and January 2020. We reviewed the medical records and assessed the clinical efficacy and toxicity using a prolonged data cutoff.
Results
In total, 164 (median age: 74 years) and 134 (median age: 68 years) patients received MONO and COMB, respectively; patients who received COMB were younger and had better performance statuses (0–1). At the prolonged data cutoff, the median follow‐up was 20.2 (range: 0.1–41.4) months. The median progression‐free survivals were 7.5 and 13.1 months, and overall survivals (OSs) were 17.2 and 33.7 months for MONO and COMB, respectively. Treatment discontinuation rates were 21.9% and 20.1% for the MONO and COMB, respectively. With prolonged follow‐up, although COMB demonstrated an OS benefit and higher objective response rate than MONO, in the propensity score matching analysis COMB didn't demonstrate a significant benefit compared to the MONO.
Conclusions
COMB may be effective as a first‐line treatment for NSCLC with high PD‐L1 expression in a selected subset of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan.
- Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan.
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
ORCID-Profile: Yasuyuki Ikezawa, Hidenori Mizugaki
Zitieren
APA
Ikezawa, Y., Morita, R., Mizugaki, H., Tateishi, K., Yokoo, K., Sumi, T., Kikuchi, H., Kitamura, Y., Nakamura, A., Kobayashi, M., Aso, M., Kimura, N., Yoshiike, F., Megumi, F., Tanaka, H., Sekikawa, M., Hachiya, T., Nakamura, K., Hommura, F., …, & Yokouchi, H. (2024). Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD ‐ L1 expression: Updated analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70036
Vancouver
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, et al. Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD ‐ L1 expression: Updated analysis. Cancer Medicine. 2024. doi:10.1002/cam4.70036
BibTeX
@article{Ikezawa2024,
author = {Ikezawa, Yasuyuki and Morita, Ryo and Mizugaki, Hidenori and Tateishi, Kazunari and Yokoo, Keiki and Sumi, Toshiyuki and Kikuchi, Hajime and Kitamura, Yasuo and Nakamura, Atsushi and Kobayashi, Maki and Aso, Mari and Kimura, Nozomu and Yoshiike, Fumiaki and Megumi, Furuta and Tanaka, Hisashi and Sekikawa, Motoki and Hachiya, Tsutomu and Nakamura, Keiichi and Hommura, Fumihiro and Sukoh, Noriaki and Ito, Kenichiro and Kikuchi, Takashi and Agatsuma, Toshihiko and Yokouchi, Hiroshi},
title = {Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD ‐ L1 expression: Updated analysis},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70036}
}
EUVIMED